Shows
WVLI News UpdateMonday, August 25, 2025CSL's plasma donation cite on Rte 50 not on closure listCSL Behring says their plasma donation center on Route 50 is not one of those scheduled to be closed by the company. Late last week it was announced Behring plans to make a 15 percent cut to its workforce and close of 22 of it's plasma donation centers in the U.S. In an email, CSL Behring representatives say the 15 percent reduction in workforce will be across their global business and won't target any one facility. The also confirmed the CSL Plasma Donation Center on Route 50 would remain open.
2025-08-2506 min
Viel Soze und scharf#04 -Bali, Behring, BundestagIn Folge 4 nehmen uns Thorsten, Shaker und Felix mit auf eine tropische Insel und wie man dort Urlaub verbringt. Ob bei der Reise dorthin Kaugummis helfen oder einfach nur bei der Fahrt durchs Saarland klären die drei genauso souverän wie die Frage nach Papier oder digital. Lokalpolitisch wird es dann beim Thema Stellenabbau beim Marburger Standort von CSL Behring.Thorsten erklärt was man von Bundestagspräsidentin Julia Klöckner lernen, bzw. besser nicht lernen sollte und es wird endgültig geklärt ob man kotzen im Podcast biepen muss.
2025-07-2133 min
The bluEPrint by Executive PlatformsA Speaker Roundtable from NAFES25 - A Finance Conversation Among Senior Executives on the Issues and Ideas that Matter MostFor this special episode of Executive Platforms' BluEPrint Podcast series we had some of the top speakers from the 2025 edition of the North American Finance Executive Summit series sit down and speak to the challenges and opportunities submitted by attendees of the event as they filled out their delegate profiles, weighted by popularity. This wide-ranging conversation will see four senior executives from four very different companies speaking to the issues, ideas, innovations, and inspirations that matter to all of them as prompted by their peers. It is a fantastic deep dive into what is most relevant to f...
2025-04-0925 min
Rare Disease DiscussionsConsider Rare: Suspecting and Diagnosing Hereditary Angioedema (HAE)Hereditary angioedema (HAE) is a rare condition often due to reduced levels C1-inhibitor, which is a protein involved in various physiological processes in plasma, most notably with the complement system. C1-inhibitor also binds and inhibits plasma kallikrein and factor XIa, thereby affecting bradykinin production. It is believed that the disruptions of these processes cause fluid to leak from the blood to connective tissue, leading to HAE attacks. Owing to its rarity, HAE is often poorly recognized, leading to misdiagnoses and significant diagnostic delays. Being aware of the early signs and symptoms of this condition can lead to faster...
2025-03-0724 min
All Things Angioedema – Learning about angioedema with Dr. Thomas ButtgereitEpisode 33 – Comorbidities in people with HAEWhat comorbidities are seen in people with HAE? Dr Linda Sundler Björkman joins Dr Thomas Buttgereit to discuss her research on comorbidities in HAE, including methodology, key findings, and the need for further research.Disclosure statement: Unrestricted research grant from CSL Behring. Honorars from Takeda, Biocryst and CSL Behring.Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.Feedback form ATA: https://forms.office.com/e/ZWxx3D4Cmr
2025-03-0423 min
IG Living Advocate PodcastA Patient’s Story: See the Difference Maintaining Steady Ig Levels Can Make in PIThis podcast is sponsored by CSL Behring, manufacturer of Hizentra, subcutaneous immune globulin. In this episode, we will discuss Melaine's journey with PI, from her experience with IVIG, to her switch to subcutaneous IG, and what that meant in terms of self-administering her treatment at home. Melaine enjoys cycling, gardening, travel and she's also living with primary immunodeficiency or PI. Melaine will be sharing her story and also providing some information about Hizentra, for which she is a patient advocate. Patient advocates are not healthcare professionals or medical experts. For medical questions or advice, please contact...
2025-01-2820 min
AllergyTalkPediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 3 – Long-Term Management and Prophylaxis for HAEHost: Kristin C. Sokol, MD, MS, MPH, FACAAI
Experts: Aleena Banerji, MD; Jonathan A. Bernstein, MD, FACAAI
Explore the strategies for long-term prophylaxis in pediatric HAE, including when to initiate treatment and the risks and benefits of various approaches. Transitioning care from childhood into adolescence and beyond is also discussed.
Learning Objective:
After listening to this podcast episode, participants should be better able to:
Employ strategies for long-term prophylaxis.
References:
Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of...
2024-12-1312 minAllergyTalkPediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 2 – Overcoming Barriers in HAE TreatmentEpisode 2: Overcoming Barriers in HAE Treatment
Host: Kristin C. Sokol, MD, MS, MPH, FACAAI
Experts: Jonathan A. Bernstein, MD, FACAAI; Timothy J. Craig, DO, FACAAI
This episode addresses the challenges of managing HAE, including treatment differences in rural vs. urban settings, barriers to care, and the importance of shared decision-making for treatment plans. Discover effective strategies for on-demand home therapy administration.
Learning Objective:
After listening to this podcast episode, participants should be better able to:
Create effective treatment plans for their specific pop...
2024-12-1320 minAllergyTalkPediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies Miniseries Episode 1 – Diagnosing HAE AccuratelyHost: Kristin C. Sokol, MD, MS, MPH, FACAAI
Experts: Aleena Banerji, MD; Timothy J. Craig, DO, FACAAI
This discussion covers the key factors in accurately diagnosing HAE, including clinical history, lab testing, and the role of genetic testing in distinguishing between HAE types. Special considerations for diagnosing pediatric patients will also be discussed.
Learning Objective:
After listening to this podcast episode, participants should be better able to:
Diagnose pediatric HAE accurately
References:
Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary...
2024-12-1316 min
Investor MotivationInvestment Deep Dive: CSL Ltd (ASX: CSL)In this episode, we analyse CSL Limited (ASX: CSL), a $134 billion market cap biotechnology company specialising in plasma-derived therapies, vaccines, and rare disease treatments. Operating in over 100 countries with 25,000 employees, CSL is a global leader in life-saving medical innovations through its core businesses, including CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor.
We explore its strong economic moat, financial health, and growth performance, including a 226% increase in dividends over the past decade. Despite recent share price dips, analysts view it as potentially undervalued by 20%.
Tune in as we discuss CSL’s long-term prospects, past re...
2024-11-2620 min
Market Access MattersExploring value demonstration in market access with Korinna Karampampa, CSL BehringKorinna Karampampa, who is Director Market Access and Pricing at CSL Behring, joins this episode to share her views on sustainable economic development. Korinna shares what led her into market access and explains what drives her to think outside the box to build and demonstrate a product's current and future value. The opinions shared in this episode are Korinna’s own views and not representative of the organisation she is working for. Send us a text
2024-09-2614 min
Sourcing Industry LandscapeEmbracing Empathy in Procurement with Dupree Jones from CSL BehringIn this episode of the Sourcing Industry Landscape Podcast, host, Dawn Tiura welcomes Dupree Jones from CSL Behring. Dupree brings over 20 years of experience in global procurement, government contracts, and vendor management, with a career that spans from managing subcontractors in Iraq to leading transformations in various industries including aerospace, retail, and pharmaceuticals. Dupree shares insights on the importance of empathy in procurement and sales. He discusses the benefits of understanding the perspectives of both buyers and suppliers, especially during challenging times like the COVID-19 pandemic. Dupree emphasizes the need for thorough research and preparation in negotiations...
2024-08-0519 min
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastAmy Shapiro, MD and Prof Pratima Chowdary, MD, FRCPATH- The ‘Clot’ Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YXF865. CME/MOC credit will be available until December 31, 2024.The ‘Clot’ Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCM...
2024-01-181h 15
PeerView Clinical Pharmacology CME/CNE/CPE VideoAmy Shapiro, MD and Prof Pratima Chowdary, MD, FRCPATH- The ‘Clot’ Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YXF865. CME/MOC credit will be available until December 31, 2024.The ‘Clot’ Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCM...
2024-01-181h 15
PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastAmy Shapiro, MD and Prof Pratima Chowdary, MD, FRCPATH- The ‘Clot’ Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YXF865. CME/MOC credit will be available until December 31, 2024.The ‘Clot’ Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCM...
2024-01-181h 15
PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastAmy Shapiro, MD and Prof Pratima Chowdary, MD, FRCPATH- The ‘Clot’ Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YXF865. CME/MOC credit will be available until December 31, 2024.The ‘Clot’ Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCM...
2024-01-181h 15PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastTruman J. Milling Jr., MD, FACEP - Reversal of Misfortune: Practical Insights for Managing Uncontrolled FXa-Inhibitor–Related BleedingThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GRP865. CME credit will be available until November 8, 2024.Reversal of Misfortune: Practical Insights for Managing Uncontrolled FXa-Inhibitor–Related Bleeding In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Ph...
2023-11-0850 minPeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastTruman J. Milling Jr., MD, FACEP - Reversal of Misfortune: Practical Insights for Managing Uncontrolled FXa-Inhibitor–Related BleedingThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GRP865. CME credit will be available until November 8, 2024.Reversal of Misfortune: Practical Insights for Managing Uncontrolled FXa-Inhibitor–Related Bleeding In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Ph...
2023-11-0850 minPeerView Clinical Pharmacology CME/CNE/CPE VideoTruman J. Milling Jr., MD, FACEP - Reversal of Misfortune: Practical Insights for Managing Uncontrolled FXa-Inhibitor–Related BleedingThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GRP865. CME credit will be available until November 8, 2024.Reversal of Misfortune: Practical Insights for Managing Uncontrolled FXa-Inhibitor–Related Bleeding In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Ph...
2023-11-0850 minPeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastTruman J. Milling Jr., MD, FACEP - Reversal of Misfortune: Practical Insights for Managing Uncontrolled FXa-Inhibitor–Related BleedingThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GRP865. CME credit will be available until November 8, 2024.Reversal of Misfortune: Practical Insights for Managing Uncontrolled FXa-Inhibitor–Related Bleeding In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Ph...
2023-11-0850 min
EMJ GOLD: Pharma news, views and analysisS05 E06: Meet GOLD's new catalyst – CSL Behring's Karen Pinachyan In this week's episode, Isabel and Jade share some snippets from the interview with GOLD's next catalyst Karen Pinachyan, Head of Medical Affairs, Europe, CSL Behring. In this teaser edition of the full interview, Karen shares his motivation for joining the pharmaceutical industry, his thoughts on how to shift the care paradigm towards personalised medicine and how he believes both industry and healthcare systems can work together to deliver more value to patients.
2023-07-1114 min
The New Horizon TalksEpisode 7: Improving Equity in Patient Access to Specialised Care and Treatments through the European Reference NetworksTo mark Rare Disease Day 2023 focused on “equity”, the New Horizon Talks turn to European initiatives which can effectively contribute to fostering equity in patients’ access to diagnosis, specialised care and treatment for rare diseases. This episode explores the role of European Reference Networks (ERNs), with a specific focus on the ERN on rare hematological diseases (EuroBloodNet). Speakers discuss achievements to date, remaining challenges, and how new policy frameworks and multi-stakeholder partnerships can help strengthen the ERNs.
Guests:
Victoria Hedley, Rare Disease Policy Manager, Newcastle University
Prof. Cédric Hermans, Head Haemostasis and Thrombos...
2023-02-2328 min
The New Horizon TalksEpisode 6: Leveraging Real World Evidence for Advanced TherapyThis episode explores how real-world evidence is changing healthcare, its value in improving patients’ outcomes, its role in supporting R&D in advanced therapy and uptake of this innovation by health systems. It will discuss issues such as how to deal with evidence gaps in HTA and the role of RWE. It will reflect on the importance of the European Health Data Space in leveraging RWE collected in Europe and its benefits for rare disease patients. It will also look at how to ensure that health data is efficiently leveraged to help the development of advanced therapy in a su...
2022-10-2720 min
BloodStreamPanel: Diversity, Equity & Inclusion in bleeding disorders, plus "living in the moment."James Maple, sitting in for Amy, and Patrick present the audio from BloodStream's Diversity, Equity, and Inclusivity panel during National Hemophilia Foundation's Bleeding Disorders Conference as well as the latest from the Let's Talk mental health segment. Plus, news from ICER on gene therapy! Show Notes: Subscribe: The BloodStream Podcast Article: Hemophilia gene therapies from BioMarin, CSL pick up an early ICER endorsement Presenting Sponsor: - Takeda, visit bleedingdisorders.com to learn more. Episode and Segme...
2022-09-231h 24
The New Horizon TalksEpisode 5: Advancing Europe's leadership in rare disease innovationThis episode explores the EU’s leadership in response to rare diseases and innovation in the area, with a special focus on advanced therapy research and development. What are the achievements made in Europe and where are the remaining gaps? How can Europe achieve leadership in innovation for rare diseases?
Guests:
Yann Le Cam, CEO, EURORDIS
Elisabetta Zanon, Director, EU Public Affairs & Advocacy, Alliance for Regenerative Medicine, Europe
2022-09-2023 min
The Mary Mavis ShowForging Your Career PathWhat does "career" mean to you? How has it changed? And how should we think about our career path or journey? These are questions I talk with my two guests who are mother and daughter.Deirdre BeVard is the Senior Vice President of R&D Strategic Operations for CSL Behring, a global pharmaceutical company. She has the accountability for CSL’s clinical trials, project management, patient relationships, trial enabling technology across six therapeutic areas—and she leads CSL’s operations in China and Japan. Including CSL, Deirdre has had thirty years of experience in numerous clinica...
2022-09-0547 min
Diabetes Knowledge into Practice PodcastFocus on CKD: Latest guidelines and therapies | With Dr David CherneyThe last two years have provided updated guidelines on management of chronic kidney disease in type 2 diabetes alongside new regulatory approvals of pharmacotherapies. In this episode we speak to Dr David Cherney about the implications of these updates and advancements.
By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.
References available here
Disclosures:
2022-08-2218 minBloodStreamA women's movement's a brewin'There is a women's movement a brewin' and Patrick & Amy have the scoop! Special guest Ashley Gregory is here to tell us all about it! Plus, Amy has a diagnosis of her own to talk about, and Jessica brings us back to The Well for a segment on growth featuring community member, Michelle Conde. Presenting Sponsor: Takeda (bleedingdisorders.com) Episode Advertiser: CSL Behring (portraitsofprogress.com) Learn more about FAIR! Contact ashley.gregory@hemofoundation.org. Show Notes: Presenting Sponsor: Takeda. Visit bleedingdisorders.co...
2022-08-1245 min
The New Horizon TalksEpisode 5: Advancing Europe’s leadership in rare disease innovation (Bonus edition)This episode explores EU’s leadership in response to rare diseases and innovation in the area, with a special focus on advanced therapy research and development. What are the achievements made in Europe and where are the remaining gaps? How can Europe achieve leadership in innovation for rare diseases? The bonus edition provides insights about the impact of the COVID-19 pandemic on rare disease patients and innovation in the field.
Guests:
Yann Le Cam, CEO, EURORDIS
Elisabetta Zanon, Director, EU Public Affairs & Advocacy, Alliance for Regenerative Medicine, Europe
2022-08-1119 min
ANA InvestigatesANA Investigates Updates in Autoimmune Encephalitis, part 2, therapeutics Last month on the podcast, we talked about updates in the diagnosis of autoimmune encephalitis. This month we turn to advances in the treatment of autoimmune encephalitis. Treating these conditions has traditionally been practitioner-dependent, and currently no FDA-approved therapies exist. But that's beginning to change. Series 3, Episode 9. Featuring: Guest: Dr. Maarten Titulaer, Erasmus MC University Medical Center Interviewer/Producer: Dr. Rohini Samudralwar, University of Pennsylvania Disclosures: Dr. Titulaer disclosed that his institution receives consulting funds form UCB, Viela Bio (Horizon), and CSL Behring, he is the co-investigator on the ExTinguish trial funded in part by Horizon, and a...
2022-07-2620 min
YB-PodcastWankdorf-PodcastIm Zusammenspiel mit Stadionpartner CSL Behring wird das erste Heimspiel der Saison gegen den FCZ unter dem Motto "Wankdorf" ausgetragen. Zur Einstimmung auf das Spiel veröffentlicht der BSC YB einen besonderen "Wankdorf-Podcast" – präsentiert von CSL Behring.
In der Ausgabe kommen prominente Gäste zu Wort: So spricht YB-Trainer Raphael Wicky über seine Laufbahn und seinen Bezug zum Wankdorf. Und YB-CEO Wanja Greuel erklärt gemeinsam mit CSL Behring-Chefin Livia Artuso, weshalb das Stadion heute überhaupt wieder Wankdorf heisst und wie die Partnerschaft entstanden ist.
Auch wenn es sich um eine einmalige Podcast-Folge handelt, dürfen sich die YB-Fans künftig a...
2022-07-131h 22BloodStreamRare Disease Podcasters on Patient-Centricity and a new segment of The Well!Patrick and Amy are joined by three of the most prolific and committed rare disease podcasters out there: Effie Parks from Once Upon A Gene, Kyle Bryant from Two Disabled Dudes, and Bo Bigelow from Stronger Every Day. Those three titans behind the mic join us for a candid discussion about patient centricity, we touch on some recent news, FLOW's Jessica Lauren Richmond is back with the latest installment of The Well. Show Notes: Subscribe to: Once Upon a Gene 2DD Stronger Everyday Re...
2022-06-101h 13
Dove Medical Press podcastsThe impact of triple therapy: Mortality in COPDDr Marc Miravitlles is back to discuss mortality analyses with Dr Richard Russell.1 They will review what the guidelines recommend for initial and follow-up treatment of COPD, who should receive inhaled corticosteroids and how we should interpret mortality analyses in the COPD field.2–4 Dr Russell will then dive into a new publication on the use of FEV3/FEV6 in early airways disease identification,5 before highlighting what’s hot on social media. This week, the focus is on Lacing Up for Lungs and promoting an active and healthy lifestyle. Don’t miss out!
1 Miravitlles M, et al. Am J Resp...
2022-04-2517 min
The Bio ReportGene Therapy Provides Hope to Hemophilia B PatientsIn 2020, CSL Behring entered into a global license and commercialization agreement with UniQure for the company’s experimental hemophilia B gene therapy. The expected, one-and-done treatment carries the potential to free people with the genetic bleeding disease from reliance on regular infusions of clotting factor IX for which they are deficient. We spoke to Steve Pascoe, senior vice president and head of therapeutic areas and development strategy for R&D at CSL about hemophilia B, how the gene therapy fits into CSL’s broader therapeutic offerings, and the encouraging results from the recent pivotal study.
2022-02-1723 minDove Medical Press podcastsTreating patients with COPD: When should we use ICS?This episode of the Medical Insider COPD podcast starts with Dr Richard Russell and Dr Marc Miravitlles as they discuss the role of inhaled corticosteroids (ICS) in COPD treatment. Listen as they describe which subgroups of patients with COPD are most likely to benefit from ICS and what clinical studies into dual bronchodilation vs. ICS reveal.1–3 Dr Russell will follow this by discussing key takeaways from a new publication on the prevalence of pulmonary embolism in patients hospitalised with COPD,4 and by talking to us about a social media hot topic – singing and COPD. Keep an eye out for futu...
2022-02-0819 min
The New Horizon TalksEpisode 4: Taking the Ethical Debate ForwardThis conversation takes a deep dive into the ethical issues surrounding cell and gene therapies. What are the main questions from patients and the broader public? What are the key myths surrounding these therapies? It explores topics such as transparency, responsibility in science and research efforts, inclusivity & non-discrimination in access.
Guest:
Hervé Chneiweiss, Chairman, INSERM Ethics Committee; Chair, UNESCO International Bioethics Committee; member, WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing
2021-10-1925 min
The New Horizon TalksEpisode 3: Advancing For and With PatientsThis podcast examines patient centricity in cell and gene therapy, exploring how care must be planned and delivered to be responsive to individual patient preferences, needs and values. What exactly does patient focus mean, when talking about advanced therapies? What should patients know before embarking on the therapy and how do patient advocacy organisations support patients in this process?
Guest:
· Durhane Wong-Rieger, Chair, Rare Disease International Council
----
Abbreviations:
· HTA: Health technology assessment
· ERNs: European reference networks
2021-10-0628 min
Data Science LeadersExploring the Future of Data: Regulations & Managing Analytics Teams (John Thompson, Global Head of Advanced Analytics & AI, CSL Behring)Between GDPR, CCPA, and more regulatory frameworks on the horizon, the landscape of personal data—and how it can be used in business—is shifting.On this episode, John Thompson, Global Head of Advanced Analytics & AI at CSL Behring, joins host Dave Cole to discuss that shift, and a potential future in which we as individuals could be compensated for the use of our data.Plus, John shares the two types of analytics teams he’s seen work well during his career as a data science leader.Topics covered include:- If and how individuals can know w...
2021-09-2845 min
The New Horizon TalksEpisode 2: Transforming the Future of Healthcare TogetherIn this episode, we look at the unique policy challenges presented by cell and gene therapies from research & development through to patient access; and the role of multi-stakeholder collaborations, in particular those active in supporting European policymaking. How can we, together, deliver these innovative therapies to patients and society, efficiently and safely?
Guests:
• Amanda Bok, Chief Executive, European Haemophilia Consortium (EHC)
• Alexander Natz, CEO, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
----
Abbreviations:
• ATMPs: Advanced therapy medicinal products
• EBMT: European Society for Blood and Marrow Transplantation
• G...
2021-09-2728 min
The New Horizon TalksEpisode 1: New Horizons for Rare Disease PatientsThis episode provides an introduction to cell and gene therapies and touches upon the historical, scientific, clinical, policy and regulatory considerations surrounding their development and use, with forward-looking perspectives from our guests on the future of this new chapter of medicine.
Guests:
· Professor Luigi Naldini, Director, San Raffaele Telethon Institute for Gene Therapy
· Avril Daly, Vice-president, Rare Diseases Europe (EURORDIS); CEO, Retina International
----
Abbreviations:
· CAR T cells: chimeric antigen receptor T cells
· HTA: Health technology assessment
2021-09-2228 min
The New Horizon TalksBonus episode: Advancing For and With PatientsThis podcast examines patient centricity in cell and gene therapy, exploring how care must be planned and delivered to be responsive to individual patient preferences, needs and values. What exactly does patient focus mean, when talking about advanced therapies? What should patients know before embarking on this therapy and how do patient advocacy organisations support patients in this process?
Guest:
• Durhane Wong-Rieger, Chair, Rare Disease International Council
Abbreviations:
· HTA: Health Technology Assessment
· ERNs: European Reference Networks
2021-08-2719 min
Event Design Collective PODcastsPierre MacNeil - ONSTAGE - Designer Series - CSL Behring Asia Pacific On Claiming TimeRuud Janssen of the Event Design Collective is having a conversation with Pierre MacNeil on his views and experiences in using Event Design using the #EventCanvas with his team at CSL Behring Asia Pacific and how it relates with Pierre's experience as an event owner in his biopharmaceutical career.
Pierre MacNeil is Head, Commercial Excellence and Customer Engagement, Asia Pacific at CSL Behring based in Hong Kong.
As a global healthcare executive with broad commercial experience including health policy shaping and market access he thrives while team-solving high stake, high pressure, complex business challenges. By leveraging data sciences and machine...
2021-07-2820 min
Event Design Collective PODcastsPierre MacNeil - BACKSTAGE - Designer Series - CSL Behring Asia Pacific On Claiming TimeRuud Janssen of the Event Design Collective is having a conversation with Pierre MacNeil on his views and experiences in using Event Design using the #EventCanvas with his team at CSL Behring Asia Pacific and how it relates with Pierre's experience as an event owner in his biopharmaceutical career.
Pierre MacNeil is Head, Commercial Excellence and Customer Engagement, Asia Pacific at CSL Behring based in Hong Kong.
As a global healthcare executive with broad commercial experience including health policy shaping and market access he thrives while team-solving high stake, high pressure, complex business challenges. By leveraging data sciences and machine...
2021-07-2820 min
Podcast de Perguntas & Respostas do WebinarPerguntas & Respostas: Webinar CSL Behring: Dra. Roseny dos Reis Rodrigues - CompletoWebinar Estratégias para implementação do protocolo de reversão de anticoagulantes antagonistas de vitamina K, nele eu entrevisto a Dra. Roseny dos Reis Rodrigues - Completo
2021-05-1118 minPodcast de Perguntas & Respostas do WebinarIntrodução - Webinar Estratégias para implementação do protocolo de reversão de anticoagulantes antagonistas de vitamina K, nele eu entrevisto a Dra. Roseny dos Reis Rodrigues.Introdução Webinar Estratégias para implementação do protocolo de reversão de anticoagulantes antagonistas de vitamina K, nele eu entrevisto a Dra. Roseny dos Reis Rodrigues.
2021-05-1100 minPodcast de Perguntas & Respostas do WebinarPergunta 01 - Dra, no Hospital onde a sra atua e implementou o protocolo, quanto tempo decorreu entre você abordar e sensibilizar os envolvidos até efetivamente conseguir implementar o protocolo?Dra, no Hospital onde a sra atua e implementou o protocolo, quanto tempo decorreu entre você abordar e sensibilizar os envolvidos até efetivamente conseguir implementar o protocolo?
2021-05-1101 minPodcast de Perguntas & Respostas do WebinarPergunta 02 - Vale à pena ter na sala de emergência o CCP para uma rápida abordagem nos casos de pacientes em uso de antagonistas da Vitamina K e que dão entrada com quadros graves de hemorragia maiorE vale a pena ter na sala de emergência o CCP para uma rápida abordagem nos casos de pacientes em uso de antagonistas da Vitamina K e que dão entrada com quadros graves de hemorragia maior?
2021-05-1100 minPodcast de Perguntas & Respostas do WebinarPergunta 03 - A reversão com concentrado de complexo protrombínico, é imediata, Dra? Em quanto tempo já consigo observar a ação desse medicamento?A reversão com concentrado de complexo protrombínico, é imediata, Dra? Em quanto tempo já consigo observar a ação desse medicamento?
2021-05-1101 minPodcast de Perguntas & Respostas do WebinarPergunta 04 - Não seria interessante definir uma proporção para transfusão maciça em trauma? Se fazemos plasma indiscriminadamente porque não fazer concentrado de complexo protrombínico mesmo sem tromNão seria interessante definir uma proporção para transfusão maciça em trauma? Se fazemos plasma indiscriminadamente porque não fazer concentrado de complexo protrombínico mesmo sem tromboelastografia ou ROTEM?
2021-05-1101 minPodcast de Perguntas & Respostas do WebinarPergunta 05 - Poderia abordar a questão de custo entre plasma fresco congelado e concentrado de complexo protrombínico?Poderia abordar a questão de custo entre plasma fresco congelado e concentrado de complexo protrombínico?
2021-05-1101 minPodcast de Perguntas & Respostas do WebinarPergunta 06 - Um participante comentou durante o webinar que ele trabalha com cirurgia cardíaca e utiliza o ROTEM quando disponível, porém a bula do CCP informa a meta pelo INR. Ele pergunta qual doseUm participante comentou durante o webinar que ele trabalha com cirurgia cardíaca e utiliza o ROTEM quando disponível, porém a bula do CCP informa a meta pelo INR. Ele pergunta qual dose deve utilizar nesse caso e se ele pode utilizar como dose 25 UI por Kg.
2021-05-1100 minPodcast de Perguntas & Respostas do WebinarPergunta 07 - O concentrado de complexo protrombínico já existe em larga escala para uso no mercado e no cenário hospitalar?O concentrado de complexo protrombínico já existe em larga escala para uso no mercado e no cenário hospitalar?
2021-05-1100 minPodcast de Perguntas & Respostas do WebinarPergunta 08 - Qual é a duração de ação do CCP? Existe alguma situação que devemos repetir a dose?Qual é a Duração de ação do CCP? Existe alguma situação em que devemos repetir a dose?
2021-05-1100 minPodcast de Perguntas & Respostas do WebinarPergunta 09 - Há indicação de fazer complexo protrombínico profilático em cirurgias eletivas? Se sim, em qual situação?Há indicação de fazer complexo protrombínico profilático em cirurgias eletivas? Se sim, em qual situação?
2021-05-1100 minPodcast de Perguntas & Respostas do WebinarPergunta 10 - Na prática clínica após a implementação do protocolo você observou redução da mortalidade?Na prática clínica após a implementação do protocolo você observou redução da mortalidade?
2021-05-1101 minPodcast de Perguntas & Respostas do WebinarPergunta 11 - Em sua experiência, existe risco de trombose no uso do concentrado de complexo protrombínico?Em sua experiência, existe risco de trombose no uso do concentrado de complexo protrombínico?
2021-05-1100 minPodcast de Perguntas & Respostas do WebinarPergunta 12 - Há alguma situação do uso de vitamina K junto com o concentrado de complexo de protrombínico?Há alguma situação do uso de vitamina K junto com o concentrado de complexo de protrombinico?
2021-05-1100 minPodcast de Perguntas & Respostas do WebinarPergunta 13 - Em casos de sangramanto intra operatório, sem uso de cumarínicos, tem indicação a utilização de concentrado de complexo protrombínico?Em casos de sangramanto intra operatório, sem uso de cumarínicos, tem indicação a utilização de concentrado de complexo protrombínico?
2021-05-1100 minPodcast de Perguntas & Respostas do WebinarPergunta 14 - É autorizado realizar bloqueio de neuroeixo após a reversão do anticoagulante antagonista de vitamina K com complexo protrombínico?É autorizado realizar bloqueio de neuroeixo após a reversão do anticoagulante antagonista de vitamina K com complexo protrombínico?
2021-05-1101 minPodcast de Perguntas & Respostas do WebinarPergunta 15 - Existe algum manuseio diferenciado do uso de concentrado de complexo protrombínico para os pacientes com insuficiência renal não dialítico?Existe algum manuseio diferenciado do uso de concentrado de complexo protrombínico para os pacientes com insuficiência renal não dialítico?
2021-05-1100 minPodcast de Perguntas & Respostas do WebinarPergunta 16 - Após o uso do CCP há segurança para cateter de peridural?Após o uso do CCP há segurança para cateter de peridural?
2021-05-1100 minPodcast de Perguntas & Respostas do WebinarPergunta 17 - Nos pacientes em ECMO, alguns serviços não usam o CCP, mas sim o plasma guiado pelo ROTEM. Essa prática é devida à preocupação de maior risco de trombose? Seria essa sua conduta?Nos pacientes em ECMO, alguns serviços não usam o CCP, mas sim o plasma guiado pelo ROTEM. Essa prática é devida a preocupação de maior risco de trombose? Seria essa sua conduta?
2021-05-1101 minPodcast de Perguntas & Respostas do WebinarPergunta 18 - Qual a sua opinião sobre uso de CCP em pacientes no intraoperatório de cirurgia cardíaca em recém-nascidos, considerando-se a fisiologia do sistema hemostático nessa idade?Qual a sua opinião sobre uso de CCP em pacientes no introperatório de Cirurgia cardíaca em recém-nascidos, considerando-se a fisiologia do sistema hemostático nessa idade?
2021-05-1100 minPodcast de Perguntas & Respostas do WebinarPergunta 19 - Quais foram seus maiores obstáculos para a implementação e continuidade do protocolo de reversão nas instituições?Quais foram seus maiores obstáculos para a implementação e continuidade do protocolo de reversão nas instituições?
2021-05-1101 minPodcast de Perguntas & Respostas do WebinarEncerramento – Perguntas & Respostas da webinar “Estratégias para implementação do protocolo de reversão de anticoagulantes antagonistas de vitamina K”.Por hoje ficamos por aqui, gostaria de agradece-los por ouvir nosso podcast! Para assistir na íntegra o webinar Estratégias para implementação do protocolo de reversão de anticoagulantes antagonistas de vitamina K acesse www.connectingminds.com.br”
Caso tenha dúvidas sobre o uso, manuseio e administração do Beriplex (concentrado de complexo protrombínico) fique à vontade para entrar em contato com nossos representantes de vendas!
Obrigado e até o próximo podcast!
2021-05-1100 min
East Meets West: A Podcast about understanding Asia Tech and how Asia Tech affects the worldCOVID-19 Vaccines and Plasma Therapy - How Healthy is CSL? (ASX:CSL)Every week we breakdown a company in a refreshingly simple way.
In this episode, Dan and Albert talk about CSL Limited. CSL is the one of largest global biotech companies in the world. It is listed on the Australian Securities Exchange and operates to deliver science therapies such as plasma-derived immunoglobulins for the treatment of immune deficiencies and neurological conditions, in its CSL Behring division, and influenza vaccines, in its Seqirus division.
In this episode we cover:
CSL's two business divisions, CSL Behring and Seqirus
How blood and plasma donations occur
What plasma-derived therapies...
2021-01-0332 min
EmatologiaEmofilia e Value Based Health Care, l'esempio di CSL BehringIntervista a Oliver Schmitt, Amministratore Delegato di CSL Behring Italia
2020-07-1305 min
HAE SpeaksEpisode 3: Ongoing Research for New HAE treatments.Tony Castaldo, CEO of the HAE Association provides an information packed update on the new HAE treatments that are being developed by 9 companies. Tune in to this podcast for the latest exciting details about this vitally important HAE research.
Here is a list of companies and their websites listed in order as they are discussed in the podcast.
BioCryst: www.biocryst.com
Kalvista: www.kalvista.com
Phavaris: pharvaris.com
Attune Pharmaceuticals: attunepharma.com
CSL Behring: www.cslbehring.com
BioMarin: www.biomarin.com
RegenxBio: w...
2020-07-0313 min
Så sjuktAvsnitt 13: Donerad blodplasma räddar livBlodplasma från 130 donationer, från helt friska donatorer – ja, det är vad som krävs för en ganska vanlig årsförbrukning för att en person med primär immunbrist ska kunna få sin immunglobulinbehandling. I det här avsnittet tar vi reda på hur läkemedelstillverkningen och arbetet med att säkra tillgången på plasma går till. Vi träffar också Erik Ståhl igen – en av alla de som är beroende av människors vilja att donera blodplasma. Avsnittet avslutas med frågelådan och Anders Fasth. Övriga medverkande: Julia Nordin, IPOPI och Michael Grövdal, medicinsk chef CSL B...
2020-06-1644 min
The Alldus Podcast - AI in ActionE90 John Thompson, Global Head of Advanced Analytics & AI at CSL BehringToday's guest is John Thompson, Global Head of Advanced Analytics & AI at CSL Behring, who are the third largest biopharmaceutical company in the world. They derive lifesaving therapies from human plasma: specializing in treating rare diseases such as hemophilia. John manages the global advanced analytics & AI team, who are responsible for building, deploying and maintaining the analytics applications and models for the global organization.
John is an accomplished operational executive who excels at building and managing innovative, growth-oriented data and technology organizations across multiple industries, with a recent focus on the healthcare and biopharmaceutical markets. John is a...
2020-05-1925 min
Så sjuktAvsnitt 12 – Så fortsätter livet i skuggan av covid-19Begränsningarna i vardagen till följd av covid-19 har tvingat oss att vänja oss vid en ny värld, väldigt annorlunda från den vi är vana vid. Planerade vårdmöten bokas av, kontakter sker främst digitalt och den som inte är i akut behov vädjas att inte belasta vården i onödan. För de som tillhör en riskgrupp kan denna nya verklighet kännas både ensam och skrämmande. Men kanske också inspirerande och hoppfull? Vi pratar med Caroline Ekström och Erik Ståhl om hur de hanterar ovissheten kring sjukd...
2020-04-2148 min
TRENDSETTERSTRENDSETTERS: CSL’s Anthony Farina Urges Marketers “To Say What They Stand For”-- Especially Now…Anthony Farina is Chief Communications Officer & Global Corporate Affairs Leader at CSL Behring—now the world’s third-largest biotechnology leader. Earlier this month, CSL Behring announced the formation of a new alliance with Japan’s Takeda Pharmaceutical Company and other international partners to develop a potential plasma-derived therapy for treating COVID-19. He commented that “Unprecedented times call for unprecedented actions. This new alliance brings together the expertise of industry leaders worldwide for scale, sustainability, and reliability.”
2020-04-2027 min
Så sjuktAvsnitt 11 ENG: Primary immunodeficiency and covid-19This is a special edition in English regarding covid-19, from the podcast Så Sjukt - – a pod about life with primary immunodeficiency. A longer version of this episode is available in Swedish. The podcast is produced by the Swedish patient organization for people with primary immunodeficiency (PIO).
The progression of the new coronavirus, covid-19, around the world affects everyone, but may especially worry those living with a chronic disease. How should people with primary immune deficiency relate to the infection? Does immunoglobulin treatment in any way protect you? And how will this outbreak affect access to healthcare and medicines in the...
2020-03-2012 min
Så sjuktAvsnitt 11: Primär immunbrist och covid-19Framfarten av det nya coronaviruset covid-19 över världen påverkar alla, men kan särskilt skapa oro för den som lever med en kronisk sjukdom. Hur bör personer som lever med primär immunbrist förhålla sig till smittan? Skyddar immunglobulin-behandlingen på något sätt? Och hur kommer detta att påverka tillgången till vård och läkemedel framöver? Med hjälp av professor Lennart Hammarström från Karolinska institutet och vår husdoktor Anders Fasth svarar vi på frågor som kommit in till patientorganisationen PIO i detta extrainsatta och högaktuella avsnitt frå...
2020-03-1927 min
Blodig alvorEpisode 7 - Hvordan føles det å vite at du har gitt barnet ditt en arvelig sykdom?I denne episoden av Blodig Alvor skal vi møte en av kvinnene som deltok i en studie som viser at flere mødre som er bærere av hemofili og har født en sønn, sliter med skyldfølelse og sorg over å gitt barnet sitt blødersykdom. Men er dette egentlig noe man skal skamme seg over?
Det skal vi spørre Charlotte von der Lippe om. Hun er spesialist i medisinsk genetikk og overlege ved Senteret for Sjeldne Diagnoser.
For det er hun som står bak studien som avdekket den psykologiske påkjenningen hos mødrene som er bærer...
2019-11-2024 min
Så sjuktAvsnitt 6: Träning! Hur funkar det för personer med primär immunbrist?I detta avsnitt så pratar Ellinor med Lars Ljungström, överläkare på infektionskliniken på Skaraborgssjukhus, om hur det är att ha primär immunbrist och träna. Ellinor berättar att hon har upptäckt att om hon tränar mindre så känner hon sig ofta hängig och blir lättare sjuk. I avsnittet får vi också lyssna på Johan Kumblad, fysioterapeut på Västerås sjukhus som reder ut vad som egentligen menas med träning och hur immunförsvaret påverkas.
Avsnittet avslutas med frågelådan ”Anders Fasth svarar och förklarar”.
Om du har frågor eller önskemål om...
2019-06-1728 min
Blodig alvorEpisode 6: Hvorfor er det så viktig med trening når man har en bløderdiagnose?I dette avsnittet av Blodig Alvor skal det handle om noe mange av oss synes er blodslit, nemlig trening. Du kjenner kanskje på at du skulle trent mer, men det er det ikke alltid hverken tiden eller motivasjonen strekker til. Fysisk aktivitet er jo viktig for alle og enhver, men har du en bløderdiagnose er det ekstra lurt å sørge for at kroppen er både sterk og smidig.
Hvorfor er det sånn? Det skal fysioterapeut Marianne Berg ved Rikshospitalet svare på. Hun skal dessuten gi oss råd og tips om trening, og hjelpe oss å finne motivasjonen til å vær...
2019-05-1623 min
Blodig alvorEpisode 5: Hvordan er det å møte helsevesenet når du har en sjelden diagnose?Selv om sjeldne sykdommer bare rammer noen ganske få, finnes det flere titalls tusen mennesker i Norge med en uvanlig diagnose. Som helsepersonell er det derfor stor sjanse for at du på ett eller annet tidspunkt møter en pasient som har en sykdom du knapt vet noe om. Hvordan håndterer du disse situasjonene best mulig? Og hva gjør du som pasient når du møter en lege, sykepleier eller tannlege som later som om de vet mer om diagnosen din enn de i virkeligheten gjør?
Disse spørsmålene skal sykepleier Siri Grønhaug ved Senter for...
2019-03-1324 min
Neurology® PodcastFebruary 12 2019 Issue1.Quality of Life Outcomes in Patients Presenting for Evaluation of Central Nervous System Tumors 2. [What's Trending]: 'Landmark study' shows brain cells revamp their DNA, perhaps sparking Alzheimer's disease. In the first segment, Dr. Ted Burns talks with Dr. Irene Katzan about her paper on quality of life outcomes in patients presenting for evaluation of central nervous system tumors. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Jerold Chun on a 'Landmark study' showing brain cells revamp their DNA, perhaps sparking Alzheimer's disease.Dr. Ted Burns has served on scientific advisory boards for Argenx...
2019-02-1120 min
Blodig alvorEpisode 4: Hvordan er det å ha mensen og føde barn når du har von Willebrands?I denne episoden av Blodig Alvor får du møte Beathe Herfjord som har von Willebrands sykdom, alvorlig grad. Hun forteller om hvordan det var å være 16 år og ha så kraftig menstruasjon at hun var nervøs for å være alene på hybelen. Hun deler også sine erfaringer fra å ha gjennomgått to svangerskap og fødsler.
Vi skal dessuten snakke med professor og lege Pål Andre Holme ved Rikshospitalet. Han gir råd til hvilke forhåndsregler du bør ta når du har von Willebrands og venter barn – enten du har en mild, moderat eller alvorlig grad a
2019-01-0733 minNeurology® PodcastJanuary 1 2019 Issue1. Continuous EEG is Associated with Favorable Hospitalization Outcomes for Critically Ill Patients. 2. [What's Trending]: Investigation of "generic" cartel. In the first segment, Dr. Andy Schomer talks with Dr. Chloe Hill on the association between continuous EEG and favorable hospitalization outcomes for critically ill patients. In the second part of the podcast, Dr. Ted Burns focuses his interview with Christopher Rowland of the Washington Post on the investigation into a generic drug "cartel." Dr. Chloe Hill has served as an epileptologist for clinical procedures or imaging studies; and has received governmental research support from the National Institutes of Health/National Institute...
2018-12-3123 min
Blodig alvorEpisode 3: Livet med blødersykdom for 60 år sidenI dag lever vi virkelig opp til tittelen vår, for i denne episoden skal vi snakke om hvordan det var å leve med blødersykdom i en tid da tilstanden rett og slett var blodig alvor.
Du skal få møte Trond Langvik som ble født som ble født med hemofili type A, alvorlig grad, i 1953. Han forteller hvordan barndomsminnene hans har blitt visket ut av store smerter, om frykten for å føre sykdommen videre til barnebarna og om hvordan det var å leve med skrekken for at behandlingen skulle smitte han med HIV. Han forteller også om hvordan det er å få...
2018-10-2528 minNeurology® PodcastSeptember 18 2018 Issue1. Cerebello-spinal tDCS in ataxia: A randomized, double-blind, sham-controlled, crossover trial2. What's Trending: Emerging therapies for spinal muscular atrophy and Duchenne muscular dystrophyDr. Jeff Ratliff talks with Dr. Alberto Benussi about his paper on cerebellar anodal and spinal cathodal transcranial direct current stimulation as a therapeutic approach for reducing symptoms in patients with neurodegenerative ataxia. In the second part of the podcast, we are featuring a discussion with Dr. Ted Burns and Stat reporter Adam Feuerstein on two emerging therapies for spinal muscular atrophy and Duchenne muscular dystrophy.DISCLOSURES: Dr. Ratliff has received speaker honoraria from Teva and US WorldMeds LLC...
2018-09-1716 min
Blodig alvorEpisode 2: Pappa – hvorfor har jeg blødersykdom?Denne episoden av Blodig alvor handler om foreldres bekymringer. For hvor mye ekstra hensyn bør man egentlig ta til et barn med blødersykdom? Hva gjør du når du når barnet ditt hyler og skriker mens du fortvilet prøver å finne en blodåre å stikke i? Og når er det egentlig på tide at barnet selv tar ansvar for egen behandling?
Dette er noen av spørsmålene vi stiller i dette avsnittet av Blodig alvor. De vi har fått med for å gi svar og gode råd er sykepleier Siri Grønhaug ved Senter for sjeldn...
2018-08-2037 min
Blodig alvorEpisode 1: Den kongelige sykdommenI dette aller første avsnittet av podkasten Blodig alvor skal vi gjøre en rese i tid i hemofiliens historie. Du skal få høre hvorfor hemofili har fått tilnavnet «den kongelige sykdommen» og at blødersykdom spilte en sentral rolle for at Rasputin fikk sin stjernestatus i tsarens Russland.
Vi skal også snakke med sykepleier Siri Grønhaug ved Senter for sjeldne diagnoser på Oslo universitetssykehus. Hun skal fortelle om de aller første behandlingene for blødersykdom og den fantastiske utviklingen som har skjedd siden da. Siri skal dessuten hjelpe oss å kaste et blikk inn i framtiden – ti...
2018-06-2024 minNeurology® PodcastMay 1 2018 Issue1. Featured Article: Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease2. What's Trending: Drug pricing This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the May 1, 2018, print issue of Neurology. In the first segment, Dr. Jeff Ratliff talks with Dr. Matthew Barrett about his paper on predictors of psychosis in Parkinson disease. For the "What's Trending" segment, Dr. Ted Burns discusses drug pricing with journalist Ike Swetlitz.DISCLOSURES: Dr. Ratliff has received a speaker honorarium from Haverford College. Dr. Barrett has received research support from Axovant Sciences, Inc. (clinical t...
2018-04-3021 minNeurology® PodcastMarch 13 2018 Issue1. Featured Article: Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence2. What's Trending: Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnosesThis Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Mark McAllister talks with Dr. Luciano Sposato about their paper on the relationship between atrial fibrillation detection and ischemic stroke recurrence. For the "What's Trending" segment, Dr. Ted Burns speaks with Dr. Mark Keegan and Dr. Nick Zalewski about their paper on idiopathic transverse myelitis and myelopathy d...
2018-03-1229 min
Alpha-1-To-One PodcastCaregiving with Cathey HorsakOn the inaugural episode of the Alpha-1-To-One Podcast, this month's host, Maria Virginia Deliz, sits down with caregiver and Alpha-1 Foundation staff member, Cathey Horsak. Horsak shares the story of how she became involved with the Alpha-1 community after her husband's death due to liver disease caused by the rare genetic condition, Alpha-1 Antitrypsin Deficiency. She also shares why caregivers to play a major role. You can reach Cathey Horsak at 800-245-6809 or chorsak@alpha1.org. The Alpha-1-To-One Podcast is a production of the Alpha-1 Foundation. Learn more a...
2018-02-2300 minNeurology® PodcastFebruary 20 2018 Issue1. Featured Article: Intravenous thrombolysis and platelet count2. What's Trending: Gene Drives, part IThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 6, 2018, issue of Neurology. In the first segment, Dr. Kevin Barrett talks with Dr. Henrik Gensicke about his article on the effect of platelet count on bleeding risk and mortality in stroke patients treated with IV thrombolysis. In the second part of the podcast, you'll hear the first part of Dr. Ted Burns' interview with Dr. Kevin Esvelt about gene drives.DISCLOSURES: Dr. Barrett serves on the editorial board of Neurology and...
2018-02-1920 minNeurology® PodcastFebruary 6 2018 IssueFeatured Article: Burnout, Wellness, and the Future of Our ProfessionThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 6, 2018, issue of Neurology. This week, Dr. Ted Burns talks with Dr. Terry Cascino about his special address on burnout and the future of neurology. DISCLOSURES: Dr. Burns is the deputy section editor of the Neurology® podcast; has served on scientific advisory boards for Argenx, UCB, and CSL Behring; has received travel funding/speaker honoraria from Argenx and Alexion; and has received support for consulting activities from UCB Pharma and CSL Behring. Dr. Cascino is t...
2018-02-0533 min
Blödigt värreAvsnitt 10: Ta kontroll och bli en tryggare förälder till blödarsjukt barnFörsta avsnittet i säsong 4 av Blödigt värre handlar om forskning och om att vara förälder, syskon och närstående till ett barn med blödarsjuka. I programmet möter vi Linda Myrin Westesson, hemofilisjuksköterska på Koagulationscentrum i Göteborg, som i två av sina studier följt föräldrar till barn med blödarsjuka; en som fokuserar på mammor och en som fokuserar på pappor.
Medverkar gör också den erfarna pappan Andres Ingves, vars son Wilhelm vi träffade i avsnitt 6 och som smygspelade fotboll utan att hans föräldrar visste om det.
I...
2018-02-0230 minNeurology® PodcastJanuary 2 2018 Issue1) Featured Article: Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy 2) What's Trending: Clinical Trials in Alzheimer Disease This Neurology® Podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the first segment, Dr. Stacey Clardy talks with Dr. Carlos Pardo about his paper on clinical biomarkers and differential diagnosis of myelitis. For the "What's Trending" segment, Dr. Ted Burns speaks with journalist Damian Garde about the recent Clinical Trials in Alzheimer Disease conference. DISCLOSURES: Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR). D...
2018-01-0128 minNeurology® PodcastDecember 5 2017 IssueShow description/summary:1) Long-term benefit of enzyme-replacement therapy in Pompe disease: A 5-year prospective study2) What's Trending: ACTH or prednisolone for infantile ataxiaThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the December 5, 2017 issue of Neurology. In the first segment, Dr. Kelly Gwathmey talks with Dr. Nadine van der Beek about her paper on enzyme-replacement therapy in Pompe disease. In the second part of the podcast, Dr. Ted Burns focuses his interview with Dr. John Mytinger on the topic of ACTH or prednisolone for infantile ataxia. DISCLOSURES: Dr. Gwathmey reports no disclosures.Dr. van...
2017-12-0419 minNeurology® PodcastNovember 21 2017 IssueShow description/summary:1) Multiparametric MRI changes persist beyond recovery in concussed adolescent hockey players 2) Neurology Today® paper on the increase in gabapentinoid prescriptionThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the November 21, 2017 issue of Neurology. In the first segment, Dr. Ted Burns talks with Dr. Kathryn Manning and Dr. Ravi Menon about their paper regarding the effects of concussion on adolescent hockey players. In the second part of the podcast, Dr. Burns focuses his interview with Dr. Christopher Goodman about a recent Neurology Today article discussing the increase in gabapentinoid prescriptions. Disclosures can b...
2017-11-2019 minNeurology® PodcastOctober 31 2017 IssueShow description/summary:1) Change in multimodal MRI markers predicts dementia risk in cerebral small vessel disease2) What's Trending: dabigatran reversal in patients with uncontrolled bleeding This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 31, 2017, issue of Neurology. In the first segment, Dr. Matthew Elliot talks with Dr. Hugh Markus about his paper multimodal MRI markers and dementia risk in cerebral small vessel disease. In the second part of the podcast, Dr. Bryan Eckerle focuses his interview with Dr. Charles Pollack on dabigatran reversal in patients with uncontrolled bleeding or receiving surgery. DISCLOSURES...
2017-10-3028 minNeurology® PodcastJuly 25 2017 IssueShow description/summary:1) Neurology and the Humanities: Discovering the patient within2) Topic of the Month: immunosuppressants in neurologyIn the first segment, Dr. Ted Burns talks with Dr. Richard Morton about his Neurology and the Humanities paper, "Discovering the Patient Within." In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Anne Cross on immunosuppressants in neurology. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Burns serves as a section editor for the Neurology® podcast; serves on advisory boards for Argenx, UCB, and CSL Behring; receives travel or speaker honoraria from Argenx and Alexion; and r...
2017-07-2423 minNeurology® PodcastJanuary 10 2017 Issue1) A Randomized, Double-Blind, Placebo-Controlled Trial of Coenzyme Q10 in Huntington's Disease 2) What's Trending: Risk assessment in Duchenne dystrophy3) Topic of the Month: Neuromuscular medicineThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 10, 2017 issue of Neurology. In the first segment, Dr. Michelle Fullard talks with Dr. Andrew McGarry about his paper on a randomized trial of coenzyme Q10 in Huntington Disease. Dr. Ted Burns talks with Dr. Sindhu Ramchandren about her Neurology: Genetics paper on Duchenne dystrophy for our "What's Trending" feature of the week. In the next part of the podcast Dr...
2017-01-1026 minNeurology® PodcastOctober 4 20161) Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up2) What's Trending: Interview with Ben Utecht about his recently published book titled: Counting the Days While My Mind Slips Away: A Love Letter to My Family3) Topic of the month: Neurology Today story about NEJM published paper on thymectomy for patients with myasthenia gravisThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Dr. Maarten Titulaer about his paper on the clinical features and long-term follow-up of anti-LGI1 encephalitis. Dr. Ted...
2016-10-0436 minNeurology® PodcastMay 24 2016 Issue1) Natural history of cavernous malformation: Systematic review and meta-analysis of 25 studies2) e-Pearl topic: Neurologic manifestations of hereditary hemorrhagic telangiectasia3) Topic of the month: Neurology Today story about new Center for Disease Control guidelines on prescribing opioids (Part 1)This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Flaherty interviews Dr. Loch Macdonald about his paper on review and meta-analysis of 25 studies about the natural history of cavernous malformation. Dr. Adam Numis is reading our e-Pearl of the week about neurologic...
2016-05-2423 min
Medizinische Fakultät - Digitale Hochschulschriften der LMU - Teil 19/19Volumentherapie mit Albumin und Hydroxyethylstärke bei Patienten mit radikaler ZystektomieIntraoperative Blutverluste können durch intravasale Flüssigkeitszufuhr kompensiert werden, wobei sowohl die Art der Infusion als auch die Menge von entscheidender Bedeutung für eine stabile Hämodynamik sind und somit das Outcome großer abdomineller Eingriffe maßgeblich beeinflussen. Des Weiteren können Katecholamine zur Aufrechterhaltung einer suffizienten Blutversorgung beitragen. Nach der ersten Anwendung weckten Katecholamine große Hoffnungen das Outcome nach Operationen deutlich zu verbessern. Bald zeigten sich jedoch insbesondere bei hohen Dosierungen Nebenwirkungen (z.B. Reduktion der Organperfusion), was zu einem Umdenken führte. „In doubt give volume“ war ein weit verbreitetes Motto, das diesem Umdenken Ausdruck verl...
2016-03-1000 min